
Pembrolizumab in PMBCL, allogeneic CD19 CAR T cells for pediatric B-cell ALL, and fetal iron overload in β-thalassemia
Blood Podcast
00:00
Pembrolizumab and PMBCL
Pembrolizumab was evaluated in a Phase 1B trial, including patients with relapsed or refractory PMBCL. The overall response rate, or OR, was 41%, with mainly grade 1 to 2 adverse events and no toxicity-related treatment discontinuations. Nivolumab also has relevant Phase 2 data in relapsed/refractor PMBCL but in combination with Brentoxamab vidoten.
Transcript
Play full episode